Related Experiment Video

Updated: Jul 17, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Thyroid hormone receptor beta mutations in the 'hot-spot region' are rare events in thyroid carcinomas

Ana Sofia Rocha1, Ricardo Marques, Inês Bento

  • 1IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Rua Roberto Frias s/n, 4200-065 Porto, Portugal. arocha@ipatimup.pt

The Journal of Endocrinology
|January 11, 2007
PubMed

Insights

Thyroid hormone receptor beta (THRB) gene mutations are not a common cause of human follicular thyroid cancer. This study found no THRB mutations in human thyroid tumors, suggesting other mechanisms drive follicular thyroid cancer development.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Thyroid cancer is the most common endocrine neoplasia.
  • Specific oncogenes like RET/PTC and BRAF are implicated in papillary thyroid carcinoma (PTC).
  • A mouse model mimicking human follicular thyroid cancer (FTC) involves a mutant thyroid hormone receptor beta (THRB)(PV).

Purpose of the Study:

  • To investigate the role of the THRB gene in human follicular thyroid carcinogenesis.
  • To determine if THRB functions as a tumor suppressor gene in human FTC.
  • To screen for THRB gene mutations in human thyroid tumors and cell lines.

Main Methods:

  • Screening of the THRB gene hot-spot region (exons 7-10) for mutations.
  • Analysis of 51 thyroid tumors and six thyroid cancer cell lines.
  • Utilized Polymerase Chain Reaction (PCR) and direct sequencing.

Main Results:

  • No mutations in the THRB gene were detected in any of the analyzed human thyroid tumors or cell lines.
  • This finding contrasts with the implications from THRB-mutant transgenic mouse models.

Conclusions:

  • THRB gene mutations do not appear to be a significant mechanism in human follicular thyroid carcinogenesis.
  • The role of THRB in human FTC may differ from its role in the studied mouse model.
  • Further research is needed to elucidate the specific genetic alterations driving human FTC.

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes: